Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The HOPE Study (Heart Outcomes Prevention Evaluation).

P Sleight

    Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
    |April 23, 2002
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Peter Joseph Wilkinson Monks.

    BMJ (Clinical research ed.)·2017
    Same author

    Low resting heart rates are associated with new-onset atrial fibrillation in patients with vascular disease: results of the ONTARGET/TRANSCEND studies.

    Journal of internal medicine·2015
    Same author

    Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies.

    Journal of internal medicine·2014
    Same author

    Cardiovascular effects of music by entraining cardiovascular autonomic rhythms music therapy update: tailored to each person, or does one size fit all?

    Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2012
    Same author

    Clinical value of baroreflex sensitivity.

    Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2012
    Same author

    Physiological aspects of blood pressure measurement.

    Proceedings of the Royal Society of Medicine·2010

    The Heart Outcomes Prevention Evaluation (HOPE) study found that ramipril, an angiotensin-converting enzyme (ACE) inhibitor, significantly reduced cardiovascular events in high-risk patients. This included a notable benefit for diabetic patients, even with modest blood pressure reduction.

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacology
    • Preventive Cardiology

    Background:

    • The Heart Outcomes Prevention Evaluation (HOPE) study investigated the efficacy of angiotensin-converting enzyme (ACE) inhibition (ramipril) and vitamin E in high-risk cardiovascular patients.
    • This review focuses on the ramipril arm, assessing its impact on the overall trial population and a significant subgroup of diabetic patients.
    • Participants were selected based on age (>55 years), existing cardiovascular disease, or diabetes with additional risk factors like smoking, hypercholesterolemia, or hypertension.

    Discussion:

    • Ramipril treatment demonstrated a significant reduction in the composite endpoint of cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke.
    • The benefits extended to reductions in stroke, MI, cardiovascular death, all-cause mortality, heart failure, and revascularization procedures.

    Related Experiment Videos

  • Notably, the positive effects were even more pronounced in the diabetic subgroup, exceeding expectations based on the modest blood pressure reduction achieved.

    • Key Insights:

    • Ramipril significantly lowered the risk of major cardiovascular events by 22% in high-risk patients, with specific risk reductions for stroke (32%), MI (20%), and cardiovascular death (26%).
    • The diabetic subgroup experienced a 25% reduction in the primary composite endpoint, indicating a substantial benefit beyond blood pressure control.
    • Evidence suggests non-blood pressure-mediated mechanisms, such as reduced angiotensin II-induced proliferation and plaque stabilization, may contribute to ramipril's efficacy.

    Outlook:

    • The HOPE study supports the use of ACE inhibitors like ramipril for cardiovascular risk reduction in patients with normal blood pressure but significant risk factors.
    • Findings suggest expanding ACE inhibitor use beyond traditional indications (hypertension, left ventricular dysfunction, diabetic microalbuminuria) to broader high-risk populations.
    • This research highlights the potential for ACE inhibitors to be considered as a prophylactic treatment similar to aspirin for selected high-risk individuals.